TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMARCA4 ATPase Domain Recombinant Protein (HEK293 expressed, >95% purity, <1EU/ug) | View SMARCA4 Products |
| Gene Delivery | SMARCA4 Lentivirus Premade Particles (full-length ORF, high titer >10^8 TU/ml) | View SMARCA4 Products |
| Benchmark Ab | Anti-SMARCA4 Recombinant positive control | View SMARCA4 Products |
| Validator | SMARCA4 siRNA Set (3 unique targets) | View SMARCA4 Products |
| Synthetic Lethality Partner | ARID1A Recombinant Protein / Lentivirus | View ARID1A Products |
| Paralog Counter-screen | SMARCA2 (BRM) ATPase Domain Protein (>90% homology) | View SMARCA2 Products |
| Complex Component | SMARCB1 (SNF5) Recombinant Protein | View SMARCB1 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity Validation | High purity (>95%) ATPase domain expressed in HEK293 with native folding, endotoxin controlled |
| Domain Selectivity (Bromodomain vs ATPase) | Domain-specific truncated recombinant proteins available with >95% purity, verified by mass spec |
| SMARCA2/SMARCA4 Isoform Selectivity | Homolog panel proteins with theoretical MW confirmation |
| Synthetic Lethality Screening (ARID1A mutant vs WT) | ARID1A Knockdown/Overexpression Lentivirus; isogenic cell line support |
| Lack of Controls | Validated benchmark antibodies included |
| False Positives in Binding/Degradation Assays | Validated SMARCA4 siRNA for specificity confirmation in cellular contexts |
Live SMARCA4 R&D Tracker
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SMARCA4 (BRG1) represents a paradigm shift in synthetic lethality approaches. Since SMARCA4 is a tumor suppressor inactivated by loss-of-function mutations, direct inhibition is not feasible; instead, current R&D exploits synthetic lethal dependencies, particularly in ARID1A-mutant cancers (ovarian, endometrial, gastric) and SMARCA4-deficient lung cancers. First-generation ATPase inhibitors (e.g., FHD-286) are entering clinics, while next-generation modalities including PROTAC degraders (targeting SMARCA2 in SMARCA4-null tumors) and molecular glues aim to overcome catalytic inhibition limitations. As resistance mutations in the ATPase domain emerge, the next wave of R&D targets allosteric sites and protein-protein interaction interfaces within the SWI/SNF complex. Major players such as Foghorn Therapeutics, Arvinas, Prelude Therapeutics, and Kymera Therapeutics are advancing dual SMARCA2/4 degraders and highly selective ATPase domain inhibitors for solid tumors like NSCLC and SCCOHT.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATPase Inhibitor (Small Molecule) | Foghorn Therapeutics, Novartis | ARID1A-mutant Ovarian Cancer, NSCLC | ATPase Activity Assay (active, high-purity SMARCA4 ATPase domain) |
| PROTAC Degrader | Arvinas, C4 Therapeutics, Prelude Therapeutics, Kymera Therapeutics | Solid Tumors (NSCLC, SCCOHT) | Ternary Complex Validation & Selectivity (full-length SMARCA4 and SMARCA2 proteins) |
| Synthetic Lethality Screen | Broad Institute, Sanger | Pan-cancer Genomic Dependencies | Isogenic Cell Lines (ARID1A mutant vs WT systems) |
| Molecular Glue | Cedilla Therapeutics | Hematologic Malignancies | Protein-Protein Interaction Assays (SMARCB1/SMARCA4 complexes) |
| Small Molecule Inhibitor (dual) | Foghorn Therapeutics, Novartis | Prostate Cancer, SCCOHT | Selectivity Assay (SMARCA4 vs SMARCA2 proteins) |
SMARCA4 Domain Architecture and Key Mutations
SMARCA4 (BRG1) encodes the catalytic ATPase subunit of the SWI/SNF chromatin remodeling complex. Key functional domains include:
- QLQ domain (UniProt P51532)
- HSA domain (UniProt P51532)
- Helicase ATP-binding domain (UniProt P51532)
Notable mutations reported in dbSNP and UniProt:
- CSS4 (UniProt VAR_068209)
- dbSNP:rs1804579 (UniProt VAR_028215)
- CSS4; dbSNP:rs281875226 (UniProt VAR_068210)
These mutations are frequently observed in SMARCA4-deficient tumors and may impact drug sensitivity or resistance.